The Angelini Lumira Biosciences Fund will invest in early-stage companies in Canada and the US.

Angelini Pharma, part of the privately-owned Angelini holding company based in Italy, has set up its corporate venturing group with an initial $35m. The Angelini Lumira Biosciences Fund (ALBF) will be managed by Lumira Ventures, a Canada-based life sciences-focused venture capital firm. Angelini Pharma has also committed $5m as a limited partner in Lumira Ventures IV, a $220m life…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

James Mawson

James Mawson is founder and chief executive of Global Venturing.